Good day, ladies and gentlemen. And welcome to The Female Health Company’s Fourth Quarter Fiscal Year 2015 Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. Please note that today’s event is being recorded. The statements made on this conference call that are not historical in nature are forward-looking statements based on the company’s current plans and strategies. Such forward-looking statements reflect the company’s current assessment of the risks and uncertainties related to its business. The company’s actual results and future developments could differ materially from those results or developments in such forward-looking statements. Factors that may cause actual results or developments to differ materially include such things as product demand and market acceptance, the timing of receipt and shipment of large orders, competition, the economic and business environment, and the impact of government pressures, currency risks, capacity, efficiency, supply constraints, the ability to execute on new business strategies and other risks detailed in the company’s press release, shareholder communications and Securities and Exchange Commission filings. For additional information regarding such risks, the company urges you to review its 10-Q and 10-K SEC filings. I would now like to turn the conference call over to Mr. O.B. Parrish. Sir, please go ahead.

Jamie, thank you. Welcome to The Female Health Company’s fourth quarter 2015 conference call. Michele Greco, our Executive Vice President and CFO, is here with me in our Chicago office. Before I get started on the FHC report, I would like to note that it is December 1st. It’s World AIDS Day and the 18th Meeting of the International Conference on AIDS, HIV/AIDS and Associated Diseases in Africa is underway in Zimbabwe. We are happy to have that conference and representative and have a program with [indiscernible] and one of those at that conference is looking out the development of PLWHA of evidence-based interventions for HIV/AIDS and Associated Disease in the post-2015. Turning to our report, this morning I will make some general comments regarding the status of the company. Then I will cover the financial results, some key factors that may impact future results and the outlook. As usual, when I refer to years, I am referring to the company’s fiscal year which ended September 30th unless otherwise noted. First, I am pleased to report that the company posted growth for the quarter and 2015. Second, my review of opportunities and challenges, since me assuming this position, we believe the company has a positive future which wants the basis for increasing shareholder value on the long-term basis. For the fourth quarter, unit sales totaled $15.7 million, up 41% from the prior year quarter. Net revenues totaled $7.2 million, an increase of 29% from $5.6 million in the prior year quarter. Gross profit increased 43% to $4.1 million or 58% of revenue, compared with $2.9 million or 52% of net revenues in the prior year quarter. Operating expenses of $3.4 million for the fourth quarter showed no increase over the prior year. Reflecting the increase revenues and flat expenses, operating…

[Operator Instructions] And we do have a question from Russell Mollen from Nine Ten Capital. Please go ahead with your question.

Hello.

Yes.

Hey. How are you doing?

Good.

Quick question for you. I know in the past you guys have kind of briefly touched on whether or not you think unit sales would be higher or lower in a given forward 12 months or something like that than they were in the previous fiscal year? Is that something that you would be have any insight on today or whether or not you think, you would be doing more than 61 million units in fiscal ’16?

We have a very specific forecast on that Russell, I assume is to what it would be.

Got it. Okay.

[Operator Instructions] Our next question comes from Jerry Falkner from RJ Falkner. Please go ahead with your question.

Hello, O.B. and Michele. How you all doing?

Hello.

Can you hear me O.B.?

Yeah.

Okay. I’m sorry. It’s hard to hear you. I was wondering if you could just elaborate a little bit on the diversification program in terms of whether you are committed to staying in The Female Health space in terms of any acquisitions that you might make [Indiscernible] that company is on the broader basis in just Female Health?

I think in reference to targets, I would break it down like this. To the extent, we have something that’s going to fit in an area where we are currently comfortable and have some expertise such as Female Health, that’s a plus. And some of the specific properties that we’re looking at right now do fit into that category. There maybe other areas that would fit into various capacities we have such as getting approvals or distribution that could also be attractive. But I would like to mention, we have been focusing on execution. We have identified some targets that represent differentiation in terms of [Technical Difficulty] and a proprietary position and some of those too are directly involved in the Female Health.

Okay. Thank you.

Our next question comes from Eric Weinstein from Chancellor Capital. Please go ahead with your question.

Thanks. Hey, O.B. I wanted you to talk a little bit about other business developments activities that are ongoing, that could help diversify the strategy, shy of doing a large transaction that is -- to what extent, are you talking to or seeking at strategic distribution partners for the current product or having other discussion as to potentially in license other products to distribute in addition to anything you might do on the M&A front?

Right. Okay. It’s a very good point. A couple of points there. First, we are looking at some different version of FC2, which would be attractive, in terms of colors in those things and would enhance the use and perhaps differentiated to some extent from our competition. Definitely, we are also exploring different version of female condom, which could broaden our reach that might provide us something in addition. In a reference to the overall program, aside from making an acquisition or purchase, the problem that we are going through could very well end up towards the possibility of licensing the product or something of that nature. So we are exploited beyond just as simple the acquisition thing.

Okay. Thanks.

Our next question comes from Peter McMullin from IPC Global. Please go ahead with your question.

Hi, OB. It’s Peter McMullin.

Hi, Peter.

Staying with the new version of FC2, but I want to talk about the operating expenses which has been running higher than usual. We expect some lowering of this into fiscal ‘16 on an apples-to-apples basis.

Expenses, we’ve been doing some investing in with evolvement some of these additional versions for FC2. We have made some investments to a substantial degree through taking out the diversification programs. If you look at those investments we have made, it is probably over a $1 million for the year and without any immediate returns we take in the long-term will have a substantial return from it. And I’d like to mention we are able to do that and pay for and have different results and being quite profitable. I think on an ongoing operating basis, we could see operating expenses driven within this, it would be more than what we are currently experiencing.

Thank you.

And ladies and gentlemen, at this time, we’ve reached the end of today’s question-and-answer session. I’d like to turn the conference call back over to management for any closing remarks.

Thank you very much for your support and we look forward to talking to you next time. Thanks.

Ladies and gentlemen, that does conclude today’s conference call. We do thank you for attending. To access the digital replay of this conference, you may dial 1-877-344-7529 or 1-412-317-0088 beginning at 2 P.M. Eastern Time today. You’ll be prompted to enter the conference number, which will be 10076672. Please record your name and company when joining. Once again today’s conference has concluded. We do thank you for joining today’s presentation. You may now disconnect your lines.